Executive summary
U.S. Patent 7,608,605 claims a transdermal testosterone topical gel and a method for maintaining therapeutically effective serum testosterone in men with hypogonadism. The claim scope centers on a tightly defined formulation matrix (testosterone, oxacyclohexadecan-2-one absorption/vehicle component, specific thickening agent range, solvent system dominated by ethanol or isopropanol plus propylene glycol and glycerin, and a polyethylene glycol crystallization inhibitor) and a performance metric (AUC0-24 increase after a single unit-dose application). The landscape is driven less by “testosterone transdermal” broadly and more by whether a generic/competitor can enter without using the oxacyclohexadecan-2-one + polyethylene glycol crystallization inhibitor + specified viscosity/pH/solvent ranges combination and still hit the claimed AUC delta.
What does US Patent 7,608,605 claim and how broad is the scope for transdermal testosterone gels?
Core claim structure: formulation + delivery method + performance window
The independent claim is a method claim that requires both:
- How the drug product is applied (topical gel applied to skin to maintain serum testosterone concentration), and
- What the gel contains and its physicochemical properties, and
- A measurable pharmacokinetic outcome tied to a unit dose after a single application.
Claim 1 elements (patent “scope skeleton”)
Claim 1 requires, in combination:
- Indication / population: treating hypogonadism in a male by maintaining therapeutically effective testosterone serum concentration.
- Dosage form: topical gel applied transdermally to the skin.
- Rheology and pH:
- Viscosity: about 2000 to about 6000 cps (units as stated in claim).
- pH: about 4 to about 8.
- Composition A to E (must all be present within stated ranges):
- (A) Testosterone: about 0.1 to about 5 wt.%
- (B) Oxacyclohexadecan-2-one: about 0.5 to about 15 wt.%
- (C) Thickening agent: about 1 to about 6 wt.%
- (D) Solvent mixture:
- (i) 60 to 75 wt.% ethanol or isopropanol (as the dominant solvent component)
- (ii) propylene glycol and glycerin as co-solvents
- (E) Crystallization inhibitor: polyethylene glycol (PEG), without in claim 1 a numeric wt.% range (that appears in claim 2).
Claim 2 narrows crystallization inhibitor level
- PEG range: about 0.001 to about 5 wt.%.
Claim 3 (embedded in claim 1 scope via dependent language) performance constraint after unit dose
Claim 1 includes the performance requirement as a limitation that appears in dependent claim 3 language in your excerpt, but functionally it adds an additional required feature when you read the dependent chain you provided:
- The composition is applied as a unit dose:
- contains about 1 to about 300 mg testosterone.
- After a single application to skin, the AUC0-24 delta is:
- circulating testosterone AUC0-24 is about 100 to about 35,000 ng·h/dL greater than the AUC0-24 without dosing.
Scope implication: If a product’s pharmacokinetic profile does not fall within the claimed AUC delta range after one application of a unit dose in the claimed testosterone mass range, the product can fall outside the claims even if it matches all formulation numbers.
Is this “composition of matter” or “method” scope?
Although the patent number is a U.S. drug patent, the claims you provided are drafted as methods. Practically, this means:
- A court typically treats formulation constraints as required for infringement because the method specifies a gel composition with particular ranges.
- A product with a substantially different formulation can avoid literal infringement, even if it produces testosterone delivery.
Key point: The claim is not just “transdermal testosterone for hypogonadism.” It is “transdermal testosterone gel that has these ranges and yields this AUC delta.”
Main “hard-to-design-around” anchor: oxacyclohexadecan-2-one
The compound oxacyclohexadecan-2-one appears as a central excipient-like component with a broad but still bounded range:
This combination with:
- viscosity 2000 to 6000 cps,
- ethanol/isopropanol 60 to 75 wt.% plus propylene glycol and glycerin,
- and a PEG crystallization inhibitor
creates a specific formulation identity.
Design-around strategy typically targets one of the required anchors (oxacyclohexadecan-2-one, PEG crystallization inhibitor, the solvent dominance window, viscosity/pH windows, or the claimed AUC delta).
How strong is the claim breadth on each parameter?
Testosterone loading (0.1 to 5 wt.%)
- This is a moderate range and typical of transdermal gels.
- It is unlikely to be a main differentiator in practice unless a competitor uses much higher or lower testosterone loading.
Oxacyclohexadecan-2-one (0.5 to 15 wt.%)
- Wide enough to accommodate formulation variations.
- Still a “signature component”: many testosterone gels use different solubilizers/penetration enhancers and do not disclose oxacyclohexadecan-2-one at these levels.
Thickening agent (1 to 6 wt.%)
- Again broad, but dependent on what thickener is used and whether it produces the claimed viscosity.
Viscosity (2000 to 6000 cps) and pH (4 to 8)
- These are measurable parameters. They act as filters for formulation substitutability.
- Many marketed gels may not hit this exact viscosity band, depending on polymer, neutralization, and solvent fraction.
Solvent system dominance (ethanol or isopropanol 60 to 75 wt.%)
- This is a fairly tight dominant-solvent window.
- Avoidance can be straightforward if a competitor uses a different solvent percentage profile (though it may impact skin permeation and required AUC delta).
PEG crystallization inhibitor (0.001 to 5 wt.%)
- This is a major second anchor. PEG is also widely used for other reasons, but the claim ties it specifically as a crystallization inhibitor.
- Literal infringement depends on the product’s structure and role; in litigation, it often becomes an evidentiary question whether the PEG is present in the required range and functions as required by the claim.
AUC0-24 delta (100 to 35,000 ng·h/dL greater)
- This is a functional pharmacokinetic limitation.
- It can be used as an infringement or non-infringement lever because it forces a performance outcome, not just composition.
How do the oxacyclohexadecan-2-one and PEG crystallization inhibitor limitations affect infringement risk?
Literal infringement: must meet all claim requirements
Because claim 1 is drafted as a unitary method requiring a gel “which comprises” all components with the stated ranges, an accused product typically must match:
- composition (A-E),
- viscosity/pH,
- unit-dose testosterone amount,
- and the AUC delta after a single application.
Failure on any one mandatory element generally avoids literal infringement.
“Equivalents” risk: likely limited by the numerical windows
Where claims include numerical ranges, doctrine-of-equivalents arguments often face scrutiny. Numeric windows create:
- a more defined territory for the claim,
- less room for “close enough” substitution,
- and more structured expert testimony on whether ranges are materially different.
What is the patent landscape around US 7,608,605 for transdermal testosterone gels in the US?
Landscape drivers (what matters for freedom-to-operate)
For a transdermal testosterone gel, the relevant US patent estate typically clusters into:
- Formulation compositions (penetration enhancers, cosolvents, polymers, crystallization inhibitors)
- Method-of-use (hypogonadism treatment, dosing regimens)
- PK/performance targets (AUC/Cmax windows, delivery kinetics)
- Manufacturing/process (mixing, stabilization, control of crystallization)
- Packaging/delivery systems (metered dose applicators, gels vs solutions)
In the specific case of 7,608,605, the claim you provided suggests a focused estate around:
- a specific excipient set including oxacyclohexadecan-2-one
- solvent dominance (ethanol/isopropanol at high fraction)
- PEG as crystallization inhibitor
- and measurable PK outcomes after unit dosing.
Practical interpretation of “scope” in a competitive context
A competitor looking to launch a generic or follow-on product would typically evaluate whether it can:
- match the required formulation anchors while staying outside numeric ranges, or
- change the formulation so it does not fall within the claimed compositional ranges, or
- change dosing such that AUC0-24 delta is outside the claimed window.
The presence of both formulation parameter limits and a PK delta is a stronger barrier than claims limited only to formulation.
When does US 7,608,605 expire and what exclusivity can extend beyond expiration?
Expiration mechanics (high-level)
US patent term generally depends on:
- filing date (20 years from earliest effective non-provisional filing), and
- potential adjustments (USPTO patent term adjustment) and delays.
Your prompt does not include the patent’s filing date, issuance date context, or PTA/PTE data, so an exact expiration date cannot be computed from the claim text alone.
Orange Book exclusivity overlay
Patent expiration alone is not the sole driver of generic entry because FDA approval may carry:
- 3-year exclusivity for new chemical entity (unlikely for testosterone base but depends on specific product),
- 5-year exclusivity for new indication/new dosing/line extension,
- and patent-protected exclusivity under Orange Book listings.
A precise Orange Book status cannot be produced from the claim excerpt alone.
Which generic entry risks exist for testosterone gels if they design around oxacyclohexadecan-2-one and PEG crystallization inhibitors?
Generic risk is mostly about whether the design-around stays outside all required ranges
If a proposed product:
- lacks oxacyclohexadecan-2-one entirely, or
- uses it outside 0.5 to 15 wt.%, or
- uses PEG outside 0.001 to 5 wt.%, or
- uses a solvent system outside 60 to 75 wt.% ethanol/isopropanol or without propylene glycol and glycerin,
- and results in viscosity and pH outside the windows,
then it can be non-infringing on formulation grounds.
But PK delta can re-create infringement risk
Even if formulation changes avoid some excipient overlap, the method claim’s AUC0-24 delta creates a scenario where:
- an alternative formulation could still deliver testosterone exposure in the claimed performance range after a unit dose.
- In that scenario, infringement turns back to whether the formulation also meets all required composition elements.
Because the claim is conjunctive, PK alone is not enough. Still, AUC can matter in litigation where defendants argue equivalence or where accused formulation is alleged to meet required ranges.
How does US 7,608,605 compare with other testosterone transdermal patent claim types?
Typical testosterone patent categories vs this claim’s focus
Compared to broader testosterone transdermal patents, 7,608,605 is narrower in four ways:
- Vehicle signature: requires oxacyclohexadecan-2-one at defined wt.%
- Crystallization inhibitor: requires PEG as a crystallization inhibitor with wt.% range (claim 2)
- Solvent profile: requires dominant ethanol/isopropanol fraction plus propylene glycol and glycerin
- Performance metric: requires an AUC0-24 delta window after a single unit dose
Comparison implication
Many competitors can potentially avoid broad “transdermal testosterone” claims, but fewer can avoid a claim that binds multiple excipient/physicochemical constraints and a PK outcome.
What formulation features are protected by US 7,608,605 for hypogonadism testosterone gels?
Protected formulation feature map (claim-to-component matrix)
| Claim feature |
Range / requirement |
Design-space implication |
| Testosterone |
0.1 to 5 wt.% |
Avoid very low or very high loading if needed |
| Oxacyclohexadecan-2-one |
0.5 to 15 wt.% |
Biggest formulation signature |
| Thickening agent |
1 to 6 wt.% |
Must match polymer level and viscosity outcome |
| Viscosity |
~2000 to ~6000 cps |
Hard numeric barrier |
| pH |
~4 to ~8 |
Hard numeric barrier |
| Ethanol/isopropanol |
60 to 75 wt.% |
Dominant solvent constraint |
| Co-solvents |
propylene glycol + glycerin |
Both required |
| Crystallization inhibitor |
PEG, 0.001 to 5 wt.% |
Another signature anchor |
| Unit dose testosterone |
1 to 300 mg |
Constrains dosing regimen |
| PK performance |
AUC0-24 delta 100 to 35,000 ng·h/dL |
Functional barrier tied to single application |
What patent litigation or regulatory events could hinge on US 7,608,605?
Litigation hinge points derived from claim language
In a dispute involving this patent, key issues typically align with the claim elements:
- Does the accused product contain oxacyclohexadecan-2-one within 0.5 to 15 wt.%?
- Does it include PEG crystallization inhibitor within 0.001 to 5 wt.%?
- Does it meet viscosity 2000 to 6000 cps and pH 4 to 8?
- Is the solvent system within 60 to 75 wt.% ethanol/isopropanol and includes propylene glycol and glycerin?
- Do AUC0-24 delta results after a single application fit 100 to 35,000 ng·h/dL?
Without the patent’s prosecution history, specification excerpts, or Orange Book listing for the relevant NDA, no exact case-specific litigation timeline can be stated.
Key Takeaways
- US 7,608,605 claims a transdermal testosterone topical gel method for hypogonadism with conjunctive formulation and performance limitations.
- The strongest claim anchors are oxacyclohexadecan-2-one (0.5 to 15 wt.%), PEG as crystallization inhibitor (0.001 to 5 wt.%), ethanol/isopropanol dominance (60 to 75 wt.%) with propylene glycol and glycerin, plus viscosity (2000 to 6000 cps) and pH (4 to 8).
- Infringement risk is high if a competing product matches these excipient and physicochemical windows and also achieves the AUC0-24 delta requirement after a single unit dose.
- PK performance is a further filter, not a substitute for matching the formulation and unit-dose limitations.
FAQs
-
Does US 7,608,605 cover testosterone patches or only topical gels?
The claim language specifies a topical gel applied to the skin for transdermal delivery.
-
Can a product infringe if it matches viscosity and pH but not oxacyclohexadecan-2-one?
No. Claim 1 requires the gel “comprises” oxacyclohexadecan-2-one within the stated wt.% range in combination with the other components.
-
Is polyethylene glycol (PEG) used for anything other than a crystallization inhibitor in the claim?
The claim requires PEG as a crystallization inhibitor, with a numeric wt.% range in claim 2.
-
How important is the solvent system in the claim?
Highly. Claim 1 specifies a mixture where ethanol or isopropanol is 60 to 75 wt.% and requires propylene glycol and glycerin as co-solvents.
-
What is the main test for infringement based on the performance limitation?
Whether, after a single application of a claimed unit dose, the AUC0-24 increase (delta) falls within about 100 to about 35,000 ng·h/dL.
References
- US Patent 7,608,605. Claims as provided in the prompt.
